Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD device for the treatment of resistant hypertension.
February 13, 2017 — Vital Images Inc. announced that it will be demonstrating new image sharing capabilities for current ...
February 10, 2017 — With the Healthcare Information and Management Systems Society’s annual meeting (HIMSS17) scheduled ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
In the past few years there have been a number of device therapies developed to treat heart failure (HF). This is partly ...
Rep. Tom Price was confirmed by the U.S. Senate as the new secretary of the Department of Health and Human Services (HHS) by a 52-47 vote early Friday morning.
Vital Images Inc. will feature its Vitrea Modular Enterprise Imaging interoperability solutions at the 2017 Healthcare Information and Management Systems Society annual meeting (HIMSS 2017), Feb. 20–23 in Orlando, Fla.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
February 9, 2017 — Sir Peter Mansfield, FRS, whose research aided the development of magnetic resonance imaging (MRI) in ...
When a pediatric patient at Children’s Hospital Los Angeles needed a custom-build stent to repair his pulmonary artery ...
eHealth Technologies and HealtheConnections, a Syracuse-based regional health information organization (RHIO) supporting health information exchange (HIE) for the 11 counties of central and northern New York, have teamed up to share medical images across the care provider community.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopping ...
Charleston Area Medical Center (CAMC) has documented reduced readmissions for congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) and other chronic conditions. Driving this success is a comprehensive strategy supported by the SmarTigr interactive patient engagement and education system from TeleHealth Services.
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a study of the IN.PACT Admiral drug-coated balloon (DCB) for a potential new indication in patients with end-stage renal disease. The randomized study will evaluate the IN.PACT Admiral DCB as a treatment for failing arteriovenous (AV) fistulas in these patients as compared to plain balloon angioplasty. The IDE approval enables Medtronic to initiate the study and gain safety and effectiveness data for the device in this investigational indication.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a ...
A new anticancer agent in development promotes regeneration of damaged heart muscle — an unexpected research finding that may help prevent congestive heart failure in the future.
GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan (regadenoson) in territories outside the U.S., Canada and Mexico. GE Healthcare will help bring improved access to Rapiscan, offering an alternative screening method for patients who are unable to undergo traditional cardiac stress imaging procedures.